Related articles:

GW Pharmaceuticals plc: 26/09/2016 GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
September 26, 2016

GW Pharmaceuticals plc: 09/08/2016 GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress
August 09, 2016

GW Pharmaceuticals plc: 02/08/2016 GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 9 August, 2016
August 02, 2016

GW Pharmaceuticals plc: 27/06/2016 GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
June 27, 2016

GW Pharmaceuticals plc: 21/06/2016 GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)
June 21, 2016

GW Pharmaceuticals plc: 05/05/2016 GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress
May 05, 2016

GW Pharmaceuticals plc: 28/04/2016 GW Pharmaceuticals to Report Q2, Half-Year Financial Results and Host Conference Call on 5 May, 2016
April 28, 2016

GW Pharmaceuticals plc: 10/02/2016 GW Pharmaceuticals plc Reports First Quarter 2016 Financial Results and Operational Progress
February 10, 2016

GW Pharmaceuticals plc: 02/02/2016 GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 10 February, 2016
February 02, 2016

GW Pharmaceuticals plc: 07/12/2015 GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2015 Financial Results and Operational Progress
December 07, 2015

GW Pharmaceuticals plc: 30/11/2015 GW Pharmaceuticals Announces Date and Time Change for Q4 and Year-End 2015 Financial Results and Conference Call
November 30, 2015

GW Pharmaceuticals plc: 24/11/2015 GW Pharmaceuticals to Report Q4 and Year-End 2015 Financial Results and Host Conference Call on 3 December, 2015
November 24, 2015

GW Pharmaceuticals plc: 27/10/2015 GW Pharmaceuticals and the Government of New South Wales Announce a Strategic Agreement to Study Epidiolex(R) and CBDV in a Clinical Trial and Research Program for Children With Epilepsy
October 27, 2015

GW Pharmaceuticals plc: 06/08/2015 GW Pharmaceuticals plc Reports Third Quarter 2015 Financial Results and Operational Progress
August 06, 2015

GW Pharmaceuticals plc: 23/07/2015 GW Pharmaceuticals to Report Q3 2015 Financial Results and Host Conference Call on 6 August, 2015
July 23, 2015

GW Pharmaceuticals plc: 21/07/2015 GW Pharmaceuticals Announces Appointment of Julian Gangolli to Board of Directors
July 21, 2015

GW Pharmaceuticals plc: 19/05/2015 GW Appoints Senior Industry Executive to President, North America and Relocates CEO to the U.S.
May 19, 2015

GW Pharmaceuticals plc: 11/05/2015 GW Pharmaceuticals plc Reports Second Quarter 2015 Financial Results and Operational Progress
May 11, 2015

GW Pharmaceuticals plc: 06/05/2015 GW Pharmaceuticals to Report Q2 2015 Financial Results and Host Conference Call on 11 May, 2015
May 06, 2015

GW Pharmaceuticals plc: 27/04/2015 GW Pharmaceuticals plc Announces US Patent Allowance for Use of Cannabidivarin (CBDV) in Treating Epilepsy
April 27, 2015

GW Pharmaceuticals plc: 04/02/2015 GW Pharmaceuticals plc Reports First Quarter 2015 Financial Results and Operational Progress
February 04, 2015

GW Pharmaceuticals plc: GW Pharmaceuticals plc Reports First Quarter 2015 Financial Results and Operational Progress
February 04, 2015

GW Pharmaceuticals plc: 27/01/2015 GW Pharmaceuticals to Report Q1, 2015 Financial Results and Host Conference Call on 4 February, 2015
January 27, 2015

GW Pharmaceuticals plc: GW Pharmaceuticals to Report Q1, 2015 Financial Results and Host Conference Call on 4 February, 2015
January 27, 2015

GW Pharmaceuticals plc: 08/01/2015 GW Pharmaceuticals and Otsuka Announce Results in First of Three Sativex(R) Phase 3 Cancer Pain Trials
January 08, 2015

GW Pharmaceuticals plc: GW Pharmaceuticals plc Reports 2014 Q4 and Full Year Financial Results
December 02, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals to Report Q4, Year-End 2014 Financial Results and Host Conference Call on 2 December, 2014
November 24, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Reports 2014 Third Quarter Financial Results
August 06, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals to Report Q3 2014 Financial Results and Host Conference Call on 6 August, 2014
July 30, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Totaling Approximately $169.8 Million on the NASDAQ Global Market and Full Exercise of Underwriters' Option to Purchase Additional ADSs
June 25, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Totaling Approximately $148 Million on NASDAQ Global Market
June 18, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Totalling Approximately $148 Million on NASDAQ Global Market
June 18, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals Announces Proposed Public Offering of ADSs
June 17, 2014

GW Pharmaceuticals plc: GW announces agreement with New York State to investigate use of CBD to treat medication-resistant epilepsies in children
June 03, 2014

GW Pharmaceuticals plc: GW Pharmaceutical's announcement regarding MOU with State of Georgia
May 27, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Reports Second Quarter 2014 Financial Results and Operational Progress
May 07, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals to Report Q2 2014 Financial Results and Host Conference Call on 7 May, 2014
April 29, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals to Report Q2 2014 and Half Year Financial Results and Host Conference Call on 7 May, 2014
April 29, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Reports First Quarter 2014 Financial Results and Operational Progress
February 05, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Reports First Quarter 2014 Financial Results and Operational Progress
February 04, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals to Report Q1 2014 Financial Results and Host Conference Call on 5 February, 2014
January 29, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Announces the Closing of its U.S. Follow-on Offering of American Depositary Shares (ADSs) on the Nasdaq Global Market and Full Exercise of Underwriters’ Option to Purchase Additional ADSs - Offering raises $101.1 million
January 14, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Announces the Closing of Its U.S. Follow-on Offering of American Depositary Shares (ADSs) on the NASDAQ Global Market and Full Exercise of Underwriters' Option to Purchase Additional ADSs
January 14, 2014

GW Pharmaceuticals plc: Ipsen and GW Pharmaceuticals plc Enter Into Agreement for Ipsen to Promote and Distribute Sativex® in Latin America
January 14, 2014

GW Pharmaceuticals plc: Ipsen and GW Pharmaceuticals plc Enter Into Agreement for Ipsen to Promote and Distribute Sativex(R) in Latin America
January 14, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Announces Pricing of U.S. Follow-On Offering of ADSs Raising $87.9 Million on NASDAQ Global Market
January 09, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals plc Announces Pricing of U.S. Follow-On Offering of ADSs Raising $87.9 Million on NASDAQ Global Market
January 08, 2014

GW Pharmaceuticals plc: GW Pharmaceuticals Files Registration Statement for Proposed Follow-On Offering
December 23, 2013

GW Pharmaceuticals plc: GW Pharmaceuticals Files Registration Statement for Proposed Follow-On Offering
December 20, 2013

GW Pharmaceuticals plc: Publication Of UK Annual Report And Accounts
December 06, 2013